.png "Senseonics Holdings Inc (AMEX: SENS)")
BTIG analyst Sean Lavin maintained a Buy rating on Senseonics Holdings Inc (AMEX: SENS) on May 10 and set a price target of $5. The company’s shares closed on Friday at $3.03.
Lavin said:
“Await Anticipated FDA Approval; Buy Although we don’t expect a ton of stock movement around this quarter’s SENS report, commentary was upbeat on the OUS market and on the company’s preparation for the anticipated US approval and launch. The $18-$20M revenue guide for 2018 was maintained; we remain above this range as we think this may include some conservatism on the early US launch. It was great to hear that the company may receive approval before the ADA meeting – this mention on timing could push shares higher.”
According to TipRanks.com, Lavin is a 5-star analyst with an average return of 14.9% and a 63.8% success rate. Lavin covers the Healthcare sector, focusing on stocks such as Tactile Systems Technology, Obalon Therapeutics Inc, and Boston Scientific Corp.
Senseonics Holdings Inc has an analyst consensus of Strong Buy, with a price target consensus of $4.88.
See today’s analyst top recommended stocks >>
Based on the recent corporate insider activity of 29 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SENS in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Senseonics Holdings, Inc. is a medical technology company, which engages in the design, development, and commercialization of implantable continuous glucose monitoring system for people with diabetes. Its products include eversense sensor, eversense smart transmitter, eversence mobile application, and eversense data management system.
